<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202774</url>
  </required_header>
  <id_info>
    <org_study_id>03-TTD-01</org_study_id>
    <nct_id>NCT00202774</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase III, Multicenter, Ramdomised, Open-label, Study to Evaluate the Safety and Efficacy of Combination Therapy With XELOX vs. Oxaliplatin and 5-FU CI as First Line Treatment in Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine time to disease progression of combination therapy
      with capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continous
      infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine time to disease progression of combination therapy
      with capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continous
      infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine time to disease progression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine safety of combination, objetive response rate, time to onset of response , duration of response, time to treatment failure, one year survival time, overall survival time</measure>
  </secondary_outcome>
  <enrollment>348</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(capecitabine, oxaliplatin, 5-fluorouracil)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Written informed consent. Men and women &gt; or = 18 years Karnofsky functional status &gt;or=70%
        at the time of enrollment in study Histologically confirmed diagnosis of CRC Patients must
        not have received chemotherapy (exception: adjuvant treatment &gt; 12 months following
        conclusion of treatment) Presence of at least one lesion detectable by two-dimensional
        measurement.. Life expectancy greater than 3 months.

        Exclusion Criteria:

        Pregnant or nursing woman Prior administration of systemic immunotherapy, chemotherapy
        (exception: 5-FU as adjuvant treatment &gt; 12 months following conclusion of treatment)
        Evidence of allergic reaction to any of the treatment components Clinically relevant
        myocardial disease or history of myocardial infarction in the past 12 months Documented or
        suspected cerebral and/or leptomeningeal metastases. Prior malignant tumour in past 5
        years, except history of basal cell skin carcinoma or pre-invasive cervical carcinoma.

        Neutrophil count &lt; 1.5 x 109/l , platelets &lt; 100 X 109/l serum creatinine &gt; 1.5 x ULN.
        Total bilirubin count &gt; 2 x ULN Alkaline Phosphatase &gt; &gt; 2.5 x ULN (&gt; 5 x ULN if there are
        hepatic metastases) Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase
        (ALT/SGPT) &gt; 2.5 x ULN (&gt; 5 x ULN if there are hepatic metastases, &gt; 10 x ULN if there are
        bone metastases) Creatinine clearance &lt; 30 ml/min Surgery within 4 weeks prior to
        enrollment in the study. Any investigational drug during the 4 weeks prior to enrolment.
        Uncontrolled active infection Any medical or psychological disorder which, in the opinion
        of the investigator, does not allow the patient to conclude the study or sign the informed
        consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Aranda</last_name>
    <role>Study Chair</role>
    <affiliation>Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo DÃ­az-Rubio</last_name>
    <role>Study Chair</role>
    <affiliation>Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer, capecitabine, oxaliplatin, 5-fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

